---
title: "Wave Life Sciences Plans To Accelerate Regulatory Engagement With Full Control Of WVE-006"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274519706.md"
datetime: "2026-02-02T13:22:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274519706.md)
  - [en](https://longbridge.com/en/news/274519706.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274519706.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274519706.md) | [English](https://longbridge.com/en/news/274519706.md)


# Wave Life Sciences Plans To Accelerate Regulatory Engagement With Full Control Of WVE-006

Feb 2 (Reuters) - WAVE Life Sciences Ltd (WVE.O) :

-   WAVE LIFE SCIENCES ANNOUNCES PLANS TO ACCELERATE REGULATORY ENGAGEMENT WITH FULL CONTROL OF WVE-006 FOR ALPHA-1 ANTITRYPSIN DEFICIENCY
-   WAVE LIFE SCIENCES LTD: PLANS TO ENGAGE FDA ON POTENTIAL ACCELERATED APPROVAL PATHWAY FOR WVE-006, WITH REGULATORY FEEDBACK ANTICIPATED MID-2026
-   WAVE LIFE SCIENCES LTD - DATA FROM 400 MG COHORT ON TRACK FOR Q1 2026
-   WAVE LIFE SCIENCES LTD: DATA FROM 600 MG SINGLE AND MULTIDOSE COHORTS ARE EXPECTED IN 2026
-   WAVE LIFE SCIENCES LTD - EXPECTS CASH RUNWAY INTO THIRD QUARTER OF 2028 Source text: Further company coverage: (WVE.O)

### 相關股票

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [Wave Life Sciences (WVE.US)](https://longbridge.com/zh-HK/quote/WVE.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Bioshares Biotech Clinical Trials Fd (BBC.US)](https://longbridge.com/zh-HK/quote/BBC.US.md)
- [SPDR Pharmac (XPH.US)](https://longbridge.com/zh-HK/quote/XPH.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)

## 相關資訊與研究

- [Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf.](https://longbridge.com/zh-HK/news/279115110.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/zh-HK/news/278556054.md)
- [AbbVie reports topline data from Phase I ABBV-295 trial](https://longbridge.com/zh-HK/news/278540526.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/zh-HK/news/279032442.md)
- [CSP International Publishes Disclosure on V2D Création Acquisition](https://longbridge.com/zh-HK/news/278778570.md)